ABSTRACT
This chapter will discuss (i) dose and fractionation
issues in the treatment of prostate cancer from both
radiobiological and clinical perspectives, (ii) normal tissue
tolerance, (iii) evidence from recent RCTs of hypofractio-
nated radiotherapy, (iv) ongoing trials that will provide
additional evidence over the next few years, (v) indica-
tions for and contraindications to hypofractionated radio-
therapy in patients with prostate cancer, and (vi) planning
and image-guided delivery considerations particular to
hypofractionated radiotherapy.
